Qinlock (ripretinib) vs Jeselhy (pimitespib) ()
Qinlock (ripretinib) vs Jeselhy (pimitespib) ()
Qinlock (ripretinib) is a kinase inhibitor approved by the FDA for the treatment of advanced gastrointestinal stromal tumors (GIST) in patients who have received prior treatment with 3 or more kinase inhibitors, including imatinib. Jeselhy (pimitespib), on the other hand, is not a medication recognized by the FDA or EMA and does not appear in the current pharmaceutical registries; thus, it may refer to an investigational drug or a drug not approved in the United States or European Union. Patients should consult with their healthcare provider to determine the most appropriate treatment option based on their specific medical condition, the approved uses of the medication, and the availability of the drug in their region.
Difference between Qinlock and Jeselhy (pimitespib)
| Metric | Qinlock (ripretinib) | Jeselhy (pimitespib) |
|---|---|---|
| Generic name | Ripretinib | Pimitespib |
| Indications | Advanced gastrointestinal stromal tumor (GIST) | Currently under investigation, not yet approved |
| Mechanism of action | KIT and PDGFRA kinase inhibitor | HSP90 inhibitor |
| Brand names | Qinlock | Jeselhy (proposed) |
| Administrative route | Oral | Unknown |
| Side effects | Alopecia, fatigue, nausea, abdominal pain, constipation, myalgia, diarrhea, decreased appetite, palmar-plantar erythrodysesthesia syndrome, vomiting | Not fully characterized due to ongoing clinical trials |
| Contraindications | None known | Not fully characterized due to ongoing clinical trials |
| Drug class | Tyrosine kinase inhibitor | HSP90 inhibitor |
| Manufacturer | Deciphera Pharmaceuticals | Taiho Pharmaceutical |
Efficacy
Qinlock (Ripretinib) and Gastric Cancer
Qinlock (ripretinib) is a kinase inhibitor primarily approved by the U.S. Food and Drug Administration (FDA) for the treatment of advanced gastrointestinal stromal tumors (GIST) after prior treatment with 3 or more kinase inhibitors, including imatinib. While Qinlock has shown efficacy in GIST, its direct application and efficacy in the treatment of gastric cancer (adenocarcinoma of the stomach) have not been established as of the current knowledge cutoff. Gastric cancer is a different entity from GIST, and the effectiveness of ripretinib for this type of cancer would require separate clinical trials and validation.
It is important to note that off-label use of medications can occur when a physician prescribes a drug for a condition other than that for which it was approved. However, any off-label use of Qinlock for gastric cancer would be based on the discretion of the prescribing physician and is not supported by specific clinical trial data for this indication. Therefore, the efficacy of Qinlock for the treatment of gastric cancer remains unverified and would not be recommended without further evidence.
Jeselhy (Pimitespib) and Gastric Cancer
Jeselhy (pimitespib) is a heat shock protein 90 (HSP90) inhibitor. As of the knowledge cutoff, Jeselhy has been studied in clinical trials for various types of cancer, including gastric cancer. HSP90 is a molecular chaperone that is involved in the proper folding and functioning of numerous client proteins, many of which are involved in cancer cell growth and survival. By inhibiting HSP90, pimitespib can disrupt the activity of these client proteins, potentially leading to the suppression of tumor growth and proliferation.
In the context of gastric cancer, pimitespib has shown some promise in early clinical trials. However, comprehensive efficacy data and approval status for Jeselhy in the treatment of gastric cancer would require detailed results from phase III clinical trials or other advanced studies. These would provide the necessary evidence to support its use in this indication. Until such data is available and regulatory approval is granted, the use of Jeselhy for gastric cancer remains investigational and should be considered in the context of clinical trials or other research settings.
Regulatory Agency Approvals
Qinlock
-
European Medical Agency (EMA), European Union
-
Food and Drug Administration (FDA), USA
-
Health Canada
-
Therapeutic Goods Administration (TGA), Australia
Jeselhy (pimitespib)
-
Pharmaceuticals and Medical Devices Agency (PMDA), Japan
Access Qinlock or Jeselhy (pimitespib) today
If Qinlock or Jeselhy (pimitespib) are not approved or available in your country (e.g. due to supply issues), you can access them via Everyone.org.
How it works
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Breeze through the paperwork
We'll guide you through the required documents for importing unapproved medicine, ensuring you have all the necessary information.
Get a personalized quote
We’ll prepare a quote for you, including medicine costs and any shipping, administrative, or import fees that may apply.
Receive your medicine
Accept the quote and we’ll handle the rest - sourcing and safely delivering your medicine.
Some text on this page has been automatically generated. Speak to your physician before you start a new treatment or medication.
Let's talk
If you have any questions, call us or send us a message through WhatsApp or email:
Contact us